Could Alnylam Pharmaceuticals, Inc. (ALNY) Stock Be the Next Big Healthcare Player?
Redburn Atlantic has recently initiated Alnylam Pharmaceuticals, Inc. (ALNY) stock to Buy rating, as announced on March 31, 2025, according to Finviz. Earlier, on March 24, 2025, JP Morgan had raised the stock from a Neutral to Overweight, setting a price target of $328 for ALNY stock. Wolfe Research also reduced Underperform rating. Additionally, Scotiabank […]
The Shocking Insider Activity Impacting Alnylam Pharmaceuticals, Inc. (ALNY) Stock
Redburn Atlantic has recently initiated Alnylam Pharmaceuticals, Inc. (ALNY) stock to Buy rating, as announced on March 31, 2025, according to Finviz. Earlier, on March 24, 2025, JP Morgan had raised the stock from a Neutral to Overweight, setting a price target of $328 for ALNY stock. Wolfe Research also reduced Underperform rating. Additionally, Scotiabank […]
Alnylam Pharmaceuticals, Inc. (ALNY) Stock: Everything You Know Could Be Wrong
Redburn Atlantic has recently initiated Alnylam Pharmaceuticals, Inc. (ALNY) stock to Buy rating, as announced on March 31, 2025, according to Finviz. Earlier, on March 24, 2025, JP Morgan had raised the stock from a Neutral to Overweight, setting a price target of $328 for ALNY stock. Wolfe Research also reduced Underperform rating. Additionally, Scotiabank […]
The Future of Alnylam Pharmaceuticals, Inc. (ALNY) Stock: Will It Underperform?
Wolfe Research has recently reduced Alnylam Pharmaceuticals, Inc. (ALNY) stock to Underperform rating, as announced on November 12, 2024, according to Finviz. Earlier, on October 16, 2024, Scotiabank had initiated the stock to Sector Outperform. Goldman also raised Buy rating with a price target of $370. Additionally, Goldman reduced Neutral rating on February 16, 2024, […]
Uncover the Reason: Why Alnylam Pharmaceuticals, Inc. (ALNY) Stock Is Trading 92.93% Above Its 52-Week Low?
Scotiabank has recently initiated Alnylam Pharmaceuticals, Inc. (ALNY) stock to Sector Outperform rating, as announced on October 16, 2024, according to Finviz. Earlier, on August 16, 2024, Goldman had raised the stock from a Neutral to Buy, setting a price target of $370 for ALNY stock. Goldman also reduced Neutral rating with a price target […]
Alnylam Pharmaceuticals, Inc. (ALNY) Stock: A Deeper Look at Its True Potential
Scotiabank has recently initiated Alnylam Pharmaceuticals, Inc. (ALNY) stock to Sector Outperform rating, as announced on October 16, 2024, according to Finviz. Earlier, on August 16, 2024, Goldman had raised the stock from a Neutral to Buy, setting a price target of $370 for ALNY stock. Goldman also reduced Neutral rating with a price target […]
Alnylam Pharmaceuticals, Inc. (ALNY) Reported a 4.38% Operating Margin Last Year—What’s the Real Story?
Scotiabank has recently initiated Alnylam Pharmaceuticals, Inc. (ALNY) stock to Sector Outperform rating, as announced on October 16, 2024, according to Finviz. Earlier, on August 16, 2024, Goldman had raised the stock from a Neutral to Buy, setting a price target of $370 for ALNY stock. Goldman also reduced Neutral rating with a price target […]
Why Did Alnylam Pharmaceuticals, Inc. (ALNY) Stock Tumble -0.28% to $295.93?
Scotiabank has recently initiated Alnylam Pharmaceuticals, Inc. (ALNY) stock to Sector Outperform rating, as announced on October 16, 2024, according to Finviz. Earlier, on August 16, 2024, Goldman had raised the stock from a Neutral to Buy, setting a price target of $370 for ALNY stock. Goldman also reduced Neutral rating with a price target […]
Uncover the Reason: Why Alnylam Pharmaceuticals, Inc. (ALNY) Stock Is Trading 99.56% Above Its 52-Week Low?
Goldman has recently raised Alnylam Pharmaceuticals, Inc. (ALNY) stock to Buy rating, as announced on August 16, 2024, according to Finviz. Earlier, on February 16, 2024, Goldman had reduced the stock from a Buy to Neutral, setting a price target of $173. Wolfe Research also initiated Peer Perform rating. Additionally, Wells Fargo initiated Equal Weight […]
Why Did Alnylam Pharmaceuticals, Inc. (ALNY) Stock See 6.95% Surge in the Last 90 Days?
Goldman has recently raised Alnylam Pharmaceuticals, Inc. (ALNY) stock to Buy rating, as announced on August 16, 2024, according to Finviz. Earlier, on February 16, 2024, Goldman had reduced the stock from a Buy to Neutral, setting a price target of $173. Wolfe Research also initiated Peer Perform rating. Additionally, Wells Fargo initiated Equal Weight […]
